|
ADVM | Adverum Biotechnologies, Inc. |
|
|
ADVM | Adverum Biotechnologies, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ -0.05 |
| Leverage | 121.02% |
| Market Cap | $ 411.2m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -183.2m |
| Margin | -2771.55% |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops candidate gene therapy products to treat eye and rare diseases. The company is headquartered in Redwood City, California.